首页> 外文期刊>Circulation research: a journal of the American Heart Association >Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform
【24h】

Human induced pluripotent stem cell-derived cardiomyocytes as an in vitro model for coxsackievirus B3-induced myocarditis and antiviral drug screening platform

机译:人类诱导的多能干细胞衍生的心肌细胞作为柯萨奇病毒B3诱导的心肌炎的体外模型和抗病毒药物筛选平台

获取原文
获取原文并翻译 | 示例
           

摘要

RATIONALE:: Viral myocarditis is a life-threatening illness that may lead to heart failure or cardiac arrhythmias. A major causative agent for viral myocarditis is the B3 strain of coxsackievirus, a positive-sense RNA enterovirus. However, human cardiac tissues are difficult to procure in sufficient enough quantities for studying the mechanisms of cardiac-specific viral infection. OBJECTIVE:: This study examined whether human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) could be used to model the pathogenic processes of coxsackievirus-induced viral myocarditis and to screen antiviral therapeutics for efficacy. METHODS AND RESULTS:: hiPSC-CMs were infected with a luciferase-expressing coxsackievirus B3 strain (CVB3-Luc). Brightfield microscopy, immunofluorescence, and calcium imaging were used to characterize virally infected hiPSC-CMs for alterations in cellular morphology and calcium handling. Viral proliferation in hiPSC-CMs was quantified using bioluminescence imaging. Antiviral compounds including interferonβ1, ribavirin, pyrrolidine dithiocarbamate, and fluoxetine were tested for their capacity to abrogate CVB3-Luc proliferation in hiPSC-CMs in vitro. The ability of these compounds to reduce CVB3-Luc proliferation in hiPSC-CMs was consistent with reported drug effects in previous studies. Mechanistic analyses via gene expression profiling of hiPSC-CMs infected with CVB3-Luc revealed an activation of viral RNA and protein clearance pathways after interferonβ1 treatment. CONCLUSIONS:: This study demonstrates that hiPSC-CMs express the coxsackievirus and adenovirus receptor, are susceptible to coxsackievirus infection, and can be used to predict antiviral drug efficacy. Our results suggest that the hiPSC-CM/CVB3-Luc assay is a sensitive platform that can screen novel antiviral therapeutics for their effectiveness in a high-throughput fashion.
机译:理由:病毒性心肌炎是威胁生命的疾病,可能导致心力衰竭或心律不齐。病毒性心肌炎的主要病因是柯萨奇病毒的B3株,这是一种正向RNA肠病毒。然而,难以获取足够数量的人心脏组织以研究心脏特异性病毒感染的机制。目的:这项研究检查了人类诱导的多能干细胞源性心肌细胞(hiPSC-CMs)是否可用于模拟柯萨奇病毒诱发的病毒性心肌炎的致病过程,并筛选抗病毒药物的疗效。方法和结果:hiPSC-CMs被表达荧光素酶的柯萨奇病毒B3株(CVB3-Luc)感染。使用明场显微镜,免疫荧光和钙成像来表征病毒感染的hiPSC-CM的细胞形态和钙处理变化。使用生物发光成像对hiPSC-CMs中的病毒增殖进行了定量。测试了包括干扰素β1,利巴韦林,吡咯烷二硫代氨基甲酸酯和氟西汀在内的抗病毒化合物在体外hiPSC-CM中消除CVB3-Luc增殖的能力。这些化合物减少hiPSC-CM中CVB3-Luc增殖的能力与先前研究中报道的药物作用一致。通过感染了CVB3-Luc的hiPSC-CM的基因表达谱进行的机理分析显示,干扰素β1治疗后病毒RNA的激活和蛋白清除途径得以激活。结论:该研究证明hiPSC-CMs表达柯萨奇病毒和腺病毒受体,易感染柯萨奇病毒,并可用于预测抗病毒药的疗效。我们的结果表明,hiPSC-CM / CVB3-Luc分析是一个敏感的平台,可以以高通量的方式筛选新型抗病毒治疗剂的有效性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号